热门资讯> 正文

Grace Therapeutics GAAP每股收益为-0.79美元

2025-06-23 20:17

Grace Therapeutics press release (NASDAQ:GRCE): FY GAAP EPS of -$0.79.
At March 31, 2025, the Company had cash and cash equivalents of $22.1 million, a net decrease of $0.9 million compared to cash and cash equivalents of $23.0 million at March 31, 2024.

More on Grace Therapeutics

Seeking Alpha’s Quant Rating on Grace Therapeutics
Historical earnings data for Grace Therapeutics
Financial information for Grace Therapeutics

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。